 |
 |
Tasimelteon
Tasimelteon is an oral compound in development for sleep and mood disorders, including Circadian Rhythm Sleep Disorders (CRSD). Examples of CRSD include transient disorders such as jet lag and chronic disorders such as shift work sleep disorder and Non-24-Hour Sleep-Wake Disorder. Tasimelteon binds selectively to the brain's melatonin receptors, which govern the body's natural sleep-wake cycle. Compounds that bind selectively to these receptors are thought to be able to help treat sleep disorders, and additionally are believed to offer potential benefits in mood disorders.
Tasimelteon has been shown to improve sleep parameters in prior clinical studies that simulated a desynchronization of the circadian clock. In two such studies, tasimelteon caused significant improvement in sleep onset and sleep maintenance without evidence of next-day residual effects. On January 19, 2010, the FDA granted orphan drug designation status for tasimelteon in Non-24-Hour Sleep-Wake Disorder in blind individuals without light perception.
For Clinical Trial Information, click here.
 |
 |